THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
<p>Aim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/489 |
| _version_ | 1797763280686546944 |
|---|---|
| author | L. E. Chekuldaeva S. V. Obuhova A. A. Simakov L. V. Poljaeva E. I. Rjazanova |
| author_facet | L. E. Chekuldaeva S. V. Obuhova A. A. Simakov L. V. Poljaeva E. I. Rjazanova |
| author_sort | L. E. Chekuldaeva |
| collection | DOAJ |
| description | <p>Aim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were randomized to receive trimetazidine 35 mg 2 times a day (intervention group) or placebo (control group) in addition to standard therapy. A daily number of angina attacks, amount of short-acting nitroglycerin tablets consumed per week, exercise tolerance by the bicycle ergometry with the calculation of the threshold power and the work capacity were assessed at baseline and after 2 months of the drugs taking, as well as 2 months after the drugs withdrawal. Results. Significant reduction in nitroglycerin tablets consumption (1 month — by 61.8%, after 2 months — 72.5%, p<0.05) were found in the intervention group compared with the control group. Low intake of nitroglycerin compared with baseline (p<0.05) was maintained for 2 months after discontinuation of study drug. Significant increase in the threshold power (1 month — by 32.3%, after 2 months — 37.5%, p<0.05) was observed in the intervention group compared to baseline and with the control group. Conclusion. Trimetazidine in the treatment of stable angina has high clinical efficacy.</p> |
| first_indexed | 2024-03-12T19:39:19Z |
| format | Article |
| id | doaj.art-5c1c7290f89c4934bb9967c02d256faa |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-12T19:39:19Z |
| publishDate | 2015-12-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-5c1c7290f89c4934bb9967c02d256faa2023-08-02T03:55:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018451552010.1234/1819-6446-2012-4-515-520489THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASEL. E. Chekuldaeva0S. V. Obuhova1A. A. Simakov2L. V. Poljaeva3E. I. Rjazanova4Медико-санитарная часть № 2, СамараМедико-санитарная часть № 2, СамараСамарский медицинский институт «Реавиз»Медико-санитарная часть № 2, СамараМедико-санитарная часть № 2, Самара<p>Aim. To study the possibility of enhancing the antianginal effect of long-acting nitrates by their combination with trimetazidine in patients with stable angina. Material and methods. Patients with ischemic heart disease (IHD, stable angina; n=55) were included into the study. Patients were randomized to receive trimetazidine 35 mg 2 times a day (intervention group) or placebo (control group) in addition to standard therapy. A daily number of angina attacks, amount of short-acting nitroglycerin tablets consumed per week, exercise tolerance by the bicycle ergometry with the calculation of the threshold power and the work capacity were assessed at baseline and after 2 months of the drugs taking, as well as 2 months after the drugs withdrawal. Results. Significant reduction in nitroglycerin tablets consumption (1 month — by 61.8%, after 2 months — 72.5%, p<0.05) were found in the intervention group compared with the control group. Low intake of nitroglycerin compared with baseline (p<0.05) was maintained for 2 months after discontinuation of study drug. Significant increase in the threshold power (1 month — by 32.3%, after 2 months — 37.5%, p<0.05) was observed in the intervention group compared to baseline and with the control group. Conclusion. Trimetazidine in the treatment of stable angina has high clinical efficacy.</p>http://www.rpcardio.ru/jour/article/view/489стенокардияишемическая болезнь сердцатриметазитдиндженерики |
| spellingShingle | L. E. Chekuldaeva S. V. Obuhova A. A. Simakov L. V. Poljaeva E. I. Rjazanova THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE Рациональная фармакотерапия в кардиологии стенокардия ишемическая болезнь сердца триметазитдин дженерики |
| title | THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_full | THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_fullStr | THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_full_unstemmed | THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_short | THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_sort | problem of interchangeability of drug products trimetazidine is an effective treatment of patients with ischemic heart disease |
| topic | стенокардия ишемическая болезнь сердца триметазитдин дженерики |
| url | http://www.rpcardio.ru/jour/article/view/489 |
| work_keys_str_mv | AT lechekuldaeva theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT svobuhova theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT aasimakov theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT lvpoljaeva theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT eirjazanova theproblemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT lechekuldaeva problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT svobuhova problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT aasimakov problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT lvpoljaeva problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease AT eirjazanova problemofinterchangeabilityofdrugproductstrimetazidineisaneffectivetreatmentofpatientswithischemicheartdisease |